Triglav Investments D.O.O. Purchases 28,700 Shares of AbbVie Inc. $ABBV

Triglav Investments D.O.O. lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 103.5% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 56,421 shares of the company’s stock after buying an additional 28,700 shares during the quarter. AbbVie makes up 0.9% of Triglav Investments D.O.O.’s holdings, making the stock its 27th largest holding. Triglav Investments D.O.O.’s holdings in AbbVie were worth $13,064,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ABBV. Norges Bank bought a new stake in AbbVie in the 2nd quarter valued at $4,288,200,000. Laurel Wealth Advisors LLC boosted its holdings in shares of AbbVie by 18,384.4% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after purchasing an additional 5,675,095 shares during the last quarter. Vanguard Group Inc. grew its position in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main grew its position in shares of AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock valued at $876,662,000 after purchasing an additional 2,969,202 shares in the last quarter. Finally, Raymond James Financial Inc. increased its holdings in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Stock Performance

Shares of AbbVie stock opened at $217.04 on Thursday. The stock has a market cap of $383.59 billion, a price-to-earnings ratio of 164.42, a price-to-earnings-growth ratio of 0.93 and a beta of 0.35. The stock has a 50 day moving average price of $223.99 and a 200-day moving average price of $219.14. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ABBV has been the subject of a number of research reports. JPMorgan Chase & Co. increased their price target on AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research note on Monday, November 3rd. Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 price objective on the stock. Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a research report on Thursday, October 9th. Raymond James Financial set a $256.00 target price on shares of AbbVie in a report on Monday, November 3rd. Finally, Hsbc Global Res upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, December 10th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, AbbVie has a consensus rating of “Moderate Buy” and an average price target of $251.50.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised FY outlook — AbbVie reported Q4 adjusted EPS of $2.71 and revenue of $16.62B, topping estimates; management gave 2026 adjusted EPS guidance of $14.37–$14.57, above consensus, supporting the view of durable profit growth. Article Title
• Positive Sentiment: Immunology momentum — Strong demand for Skyrizi (+32% Y/Y) and Rinvoq (+29% Y/Y) drove the beat and are cited by management as the engine of revenue growth, partially offsetting Humira declines. Analysts point to continued upside from these franchises. Article Title
• Positive Sentiment: Rinvoq label expansion in progress — AbbVie submitted regulatory applications for Rinvoq (upadacitinib) in vitiligo (FDA/EMA), a meaningful new indication if approved that could support longer‑term growth. Article Title
• Neutral Sentiment: Analyst positioning mixed — Some firms (e.g., Evercore) kept bullish ratings citing immunology strength and neurology upside, while others are pausing to re‑assess targets; this is keeping trading volatile. Article Title
• Negative Sentiment: Q1 guidance missed expectations — AbbVie issued Q1 2026 EPS guidance of $2.97–$3.01 versus a ~ $3.11 consensus, and revenue guidance came in below forecasts, prompting concern about near‑term growth momentum. (Company guidance update)
• Negative Sentiment: Segment weakness and diversification worries — Aesthetics (Botox/Cosmetics) and parts of oncology showed declines and some reports flag that growth is concentrated in immunology; commentators warn the company may lean on M&A/IPR&D to sustain growth. Article Title
• Negative Sentiment: Investor skepticism on Rinvoq contribution and valuation questions — Some coverage highlights that Rinvoq’s role vs. expectations (and valuation implications for the company) remains under scrutiny despite the drug’s growth. Article Title

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.